

Accepted Manuscript

Alectinib for patients with *ALK* rearrangement–positive non–small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401)

Eiji Iwama, MD, PhD, Yasushi Goto, MD, PhD, Haruyasu Murakami, MD, PhD, Taishi Harada, MD, PhD, Shinsuke Tsumura, MD, Hiroyuki Sakashita, MD, PhD, Yoshiaki Mori, MD, PhD, Noriaki Nakagaki, MD, Yuka Fujita, MD, PhD, Masahiro Seike, MD, PhD, Akihiro Bessho, MD, PhD, Manabu Ono, MD, PhD, Akihito Okazaki, MD, Hiroaki Akamatsu, MD, Ryotaro Morinaga, MD, Shinichiro Ushijima, MD, Takayuki Shimose, Mmath, Shoji Tokunaga, PhD, Akinobu Hamada, PhD, Nobuyuki Yamamoto, MD, PhD, Yoichi Nakanishi, MD, PhD, Kenji Sugio, MD, PhD, Isamu Okamoto, MD, PhD

PII: S1556-0864(17)30123-5

DOI: [10.1016/j.jtho.2017.02.012](https://doi.org/10.1016/j.jtho.2017.02.012)

Reference: JTHO 516

To appear in: *Journal of Thoracic Oncology*

Received Date: 25 December 2016

Revised Date: 5 February 2017

Accepted Date: 16 February 2017

Please cite this article as: Iwama E, Goto Y, Murakami H, Harada T, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Okazaki A, Akamatsu H, Morinaga R, Ushijima S, Shimose T, Tokunaga S, Hamada A, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I, Alectinib for patients with *ALK* rearrangement–positive non–small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401), *Journal of Thoracic Oncology* (2017), doi: 10.1016/j.jtho.2017.02.012.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Revised version: JTO-D-16-01509R2

Brief Report

**Alectinib for patients with *ALK* rearrangement–positive non–small cell lung cancer
and a poor performance status (Lung Oncology Group in Kyushu 1401)**

Running title: Alectinib for *ALK*-positive patients with a poor PS

Eiji Iwama, MD, PhD,¹ Yasushi Goto, MD, PhD,² Haruyasu Murakami, MD, PhD,³ Taishi Harada, MD, PhD,¹ Shinsuke Tsumura, MD,⁴ Hiroyuki Sakashita, MD, PhD,^{5,6} Yoshiaki Mori, MD, PhD,⁷ Noriaki Nakagaki, MD,⁸ Yuka Fujita, MD, PhD,⁹ Masahiro Seike, MD, PhD,¹⁰ Akihiro Bessho, MD, PhD,¹¹ Manabu Ono, MD, PhD,¹² Akihito Okazaki, MD,¹³ Hiroaki Akamatsu, MD,¹⁴ Ryotaro Morinaga, MD,¹⁵ Shinichiro Ushijima, MD,¹⁶ Takayuki Shimose, Mmath,¹⁷ Shoji Tokunaga, PhD,¹⁸ Akinobu Hamada, PhD,¹⁹ Nobuyuki Yamamoto, MD, PhD,¹⁴ Yoichi Nakanishi, MD, PhD,¹ Kenji Sugio, MD, PhD,²⁰ and Isamu Okamoto, MD, PhD¹

¹Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

²Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

³Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

⁴Department of Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto, Japan.

⁵Department of Clinical Oncology, Tokyo Medical and Dental University, Tokyo, Japan.

⁶Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

⁷Department of Respiratory Medicine, Iwate Prefectural Central Hospital, Morioka, Japan.

⁸Department of Respiratory Medicine, Steel Memorial Yawata Hospital, Kita-Kyushu, Japan.

Download English Version:

<https://daneshyari.com/en/article/5701499>

Download Persian Version:

<https://daneshyari.com/article/5701499>

[Daneshyari.com](https://daneshyari.com)